Ravens Sub, a Gilead Subsidiary, Completes Acquisition of Arcellx, Inc.

Why It Matters

The cash‑only settlement and accelerated expirations reshape the risk profile for ACLX option holders, prompting immediate portfolio adjustments. The transaction also illustrates how corporate events trigger swift regulatory actions that affect market liquidity and pricing.

Key Takeaways

• Gilead subsidiary Ravens Sub completed Arcellx tender offer on April 27, 2026
• ACLX shareholders receive $115 cash and a $5 CVR per share
• OCC adjusted ACLX/1ACLX options to $11,500 cash deliverable per contract
• ACLX options expiring after May 15 2026 now expire on that date
• Exercise‑by‑exception threshold set to $0.01 for all ACLX option series

Pulse Analysis

The acquisition of Arcellx by Gilead’s Ravens Sub underscores a growing trend of biotech consolidation, where cash‑rich majors absorb innovative smaller firms to broaden pipelines. Shareholders benefit from an immediate $115 cash payout per share, while the $5 contingent value right ties future upside to specific milestones, aligning interests between the acquirer and former Arcellx investors. This structure balances certainty with performance‑based incentives, a model increasingly favored in high‑growth sectors where valuation volatility can be pronounced.

From a derivatives perspective, the Options Clearing Corporation (OCC) swiftly applied Rule 807, converting ACLX/1ACLX options to a pure cash settlement of $11,500 per contract. By accelerating expirations to May 15, 2026 and setting a $0.01 exercise‑by‑exception threshold, the OCC eliminates ambiguity around option exercise decisions and ensures orderly market functioning. Traders must now recalibrate pricing models, accounting for the reduced time horizon and the removal of the underlying share deliverable, which can compress bid‑ask spreads and affect volatility estimates.

Regulators and clearing members view such adjustments as essential safeguards that preserve market integrity during corporate events. For investors, the key takeaway is the need for rapid assessment of option positions when cash settlements and expiration changes occur, as these can materially impact portfolio risk and return. Monitoring OCC memos and understanding the mechanics of CVRs will be critical for anyone holding ACLX securities or related derivatives, ensuring they capture the cash benefit while managing any residual exposure to milestone outcomes.

Deal Summary

On April 27, 2026, Ravens Sub, Inc., a wholly owned subsidiary of Gilead Sciences, completed its tender offer for Arcellx, Inc., and the merger was consummated before market open on April 28, 2026. Shareholders receive $115 cash per share plus a contingent value right. The OCC memo details option adjustments following the transaction.